Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)

China · Delayed Price · Currency is CNY

58.47

+0.68 (1.18%)

At close: Aug 27, 2026

-26.14% (1Y)

Market Cap	26.88B -29.4%
Revenue (ttm)	968.83M +89.5%
Net Income	-597.06M
EPS	-1.29
Shares Out	465.17M
PE Ratio	n/a
Forward PE	21.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,217,470
Open	57.56
Previous Close	57.79
Day's Range	56.61 - 58.75
52-Week Range	35.73 - 84.91
Beta	-0.03
Analysts	Buy
Price Target	83.00 (+41.95%)
Earnings Date	Aug 21, 2026

About SHA:688192

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. Dizal (Jiangsu) Pharmaceutical Co., L... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2017

Employees 1,009

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688192

Full Company Profile

Financial Performance

In 2025, SHA:688192's revenue was 801.14 million, an increase of 122.60% compared to the previous year's 359.90 million. Losses were -764.05 million, -9.68% less than in 2024.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 688192 stock is "Buy." The 12-month stock price target is ¥83.00, which is an increase of 41.95% from the latest price.

Price Target

¥83.00

(41.95% upside)

Analyst Consensus: Buy

Stock Forecasts